223 related articles for article (PubMed ID: 14753746)
1. The nitrogen-containing bisphosphonate, zoledronic acid, influences RANKL expression in human osteoblast-like cells by activating TNF-alpha converting enzyme (TACE).
Pan B; Farrugia AN; To LB; Findlay DM; Green J; Lynch K; Zannettino AC
J Bone Miner Res; 2004 Jan; 19(1):147-54. PubMed ID: 14753746
[TBL] [Abstract][Full Text] [Related]
2. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines.
Nakashima T; Kobayashi Y; Yamasaki S; Kawakami A; Eguchi K; Sasaki H; Sakai H
Biochem Biophys Res Commun; 2000 Sep; 275(3):768-75. PubMed ID: 10973797
[TBL] [Abstract][Full Text] [Related]
3. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts.
Viereck V; Emons G; Lauck V; Frosch KH; Blaschke S; Gründker C; Hofbauer LC
Biochem Biophys Res Commun; 2002 Mar; 291(3):680-6. PubMed ID: 11855844
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory action of bisphosphonates on bone resorption does not involve the regulation of RANKL and OPG expression.
Kim YH; Kim GS; Jeong-Hwa B
Exp Mol Med; 2002 May; 34(2):145-51. PubMed ID: 12085990
[TBL] [Abstract][Full Text] [Related]
6. Isopropanolic extract of black cohosh stimulates osteoprotegerin production by human osteoblasts.
Viereck V; Gründker C; Friess SC; Frosch KH; Raddatz D; Schoppet M; Nisslein T; Emons G; Hofbauer LC
J Bone Miner Res; 2005 Nov; 20(11):2036-43. PubMed ID: 16234977
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions.
Quinn JM; Itoh K; Udagawa N; Hausler K; Yasuda H; Shima N; Mizuno A; Higashio K; Takahashi N; Suda T; Martin TJ; Gillespie MT
J Bone Miner Res; 2001 Oct; 16(10):1787-94. PubMed ID: 11585342
[TBL] [Abstract][Full Text] [Related]
8. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin.
Shiotani A; Takami M; Itoh K; Shibasaki Y; Sasaki T
Anat Rec; 2002 Oct; 268(2):137-46. PubMed ID: 12221720
[TBL] [Abstract][Full Text] [Related]
9. Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease.
Valverde P; Kawai T; Taubman MA
J Bone Miner Res; 2004 Jan; 19(1):155-64. PubMed ID: 14753747
[TBL] [Abstract][Full Text] [Related]
10. Production of prostaglandin D(2) by human osteoblasts and modulation of osteoprotegerin, RANKL, and cellular migration by DP and CRTH2 receptors.
Gallant MA; Samadfam R; Hackett JA; Antoniou J; Parent JL; de Brum-Fernandes AJ
J Bone Miner Res; 2005 Apr; 20(4):672-81. PubMed ID: 15765187
[TBL] [Abstract][Full Text] [Related]
11. Expression of RANKL and OPG correlates with age-related bone loss in male C57BL/6 mice.
Cao J; Venton L; Sakata T; Halloran BP
J Bone Miner Res; 2003 Feb; 18(2):270-7. PubMed ID: 12568404
[TBL] [Abstract][Full Text] [Related]
12. Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts.
Takami M; Takahashi N; Udagawa N; Miyaura C; Suda K; Woo JT; Martin TJ; Nagai K; Suda T
Endocrinology; 2000 Dec; 141(12):4711-9. PubMed ID: 11108286
[TBL] [Abstract][Full Text] [Related]
13. Alpha-lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio in human bone marrow stromal cells.
Koh JM; Lee YS; Byun CH; Chang EJ; Kim H; Kim YH; Kim HH; Kim GS
J Endocrinol; 2005 Jun; 185(3):401-13. PubMed ID: 15930166
[TBL] [Abstract][Full Text] [Related]
14. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts.
Thomas GP; Baker SU; Eisman JA; Gardiner EM
J Endocrinol; 2001 Aug; 170(2):451-60. PubMed ID: 11479141
[TBL] [Abstract][Full Text] [Related]
15. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Bone; 2005 May; 36(5):812-9. PubMed ID: 15794927
[TBL] [Abstract][Full Text] [Related]
16. Osteoblasts provide a suitable microenvironment for the action of receptor activator of nuclear factor-kappaB ligand.
Yamamoto Y; Udagawa N; Matsuura S; Nakamichi Y; Horiuchi H; Hosoya A; Nakamura M; Ozawa H; Takaoka K; Penninger JM; Noguchi T; Takahashi N
Endocrinology; 2006 Jul; 147(7):3366-74. PubMed ID: 16627581
[TBL] [Abstract][Full Text] [Related]
17. Hyaluronan increases RANKL expression in bone marrow stromal cells through CD44.
Cao JJ; Singleton PA; Majumdar S; Boudignon B; Burghardt A; Kurimoto P; Wronski TJ; Bourguignon LY; Halloran BP
J Bone Miner Res; 2005 Jan; 20(1):30-40. PubMed ID: 15619667
[TBL] [Abstract][Full Text] [Related]
18. Long wave ultrasound may enhance bone regeneration by altering OPG/RANKL ratio in human osteoblast-like cells.
Maddi A; Hai H; Ong ST; Sharp L; Harris M; Meghji S
Bone; 2006 Aug; 39(2):283-8. PubMed ID: 16567138
[TBL] [Abstract][Full Text] [Related]
19. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts.
Yu X; Huang Y; Collin-Osdoby P; Osdoby P
J Bone Miner Res; 2004 Dec; 19(12):2065-77. PubMed ID: 15537451
[TBL] [Abstract][Full Text] [Related]
20. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey EL; Williams JH; Davie MW; Marshall MJ
Bone; 2006 May; 38(5):652-61. PubMed ID: 16298558
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
